NOTCH3 and pulmonary arterial hypertension: Thus, both JAG-1 overexpression studies in normal sPASMCs and PAH sPASMCs confirmed that the administration of anti-NOTCH3 Ab 28042 displayed a targeted reduction in the NOTCH3-JAG-1 pathway with consequential amelioration of sPASMC proliferation [14].